Medtronic to expand cardiovascular products with acquisition of Invatec

28 January 2010

Your browser does not support inline frames or is currently configured not to display inline frames. Medtronic, Inc. (NYSE:MDT) has announced that it will acquire Invatec, a developer of innovative medical technologies for the interventional treatment of cardiovascular disease, and two affiliated companies: Fogazzi, which provides polymer technology to Invatec; and Krauth Cardiovascular, which distributes Invatec products in Germany.

Medtronic will make an initial payment of $350 million to Invatec and additional payments of up to $150 million for Invatec’s achievement of specific milestones.

Invatec’s array of stents, angioplasty balloons and accessory products complement therapies and products in Medtronic’s CardioVascular business, adding a robust peripheral franchise and pipeline, while enhancing its coronary product offering. Notably, Invatec has brought four drug-eluting balloons to market, covering the coronaries and lower-extremity vessels — the only company worldwide with this distinction. It is a pioneer in the development and commercialization of lesion-specific solutions, including therapies for below-the-knee and carotid artery disease.

“Medtronic’s acquisition of Invatec will accelerate the growth of our CardioVascular business, adding important new products for the coronary and peripheral vascular markets,” said Scott Ward, senior vice president at Medtronic and president of the CardioVascular business.

“Invatec brings to Medtronic an established international business with a European center of technology development and manufacturing, as well as a strong history of delivering products and high-value solutions to the interventional market,” said Andrea Venturelli, co-founder, chief executive and technical officer of Invatec.

Invatec co-founder Stefan Widensohler, vice president of global sales and marketing, said, “Our integration into Medtronic creates a tremendous opportunity to leverage Medtronic’s global scale and scope across geographies and functions, from R&D to sales and marketing, to advance the interventional treatment of cardiovascular disease.”

Cardiovascular interventions represent the largest sector of the world medical device market, generating $10 billion annually on a global basis. A significant growth opportunity within this sector is peripheral vascular disease, a large and underserved market currently estimated at US$2 billion annually and growing faster than 10 percent per year.

Approximately 20 million people in the United States and Western Europe alone suffer from peripheral vascular disease, which causes pain, reduces mobility, inhibits wound healing and leads to approximately 250,000 amputations per year.

Medtronic says that with Invatec will be better positioned to address these and other unmet clinical needs in the treatment of cardiovascular disease, the world’s leading cause of death.

	Medtronic to expand cardiovascular products with acquisition of Invatec 28 January 2010 Your browser does not support inline frames or is currently configured not to display inline frames. Medtronic, Inc. (NYSE:MDT) has announced that it will acquire Invatec, a developer of innovative medical technologies for the interventional treatment of cardiovascular disease, and two affiliated companies: Fogazzi, which provides polymer technology to Invatec; and Krauth Cardiovascular, which distributes Invatec products in Germany. Medtronic will make an initial payment of $350 million to Invatec and additional payments of up to $150 million for Invatec’s achievement of specific milestones. Invatec’s array of stents, angioplasty balloons and accessory products complement therapies and products in Medtronic’s CardioVascular business, adding a robust peripheral franchise and pipeline, while enhancing its coronary product offering. Notably, Invatec has brought four drug-eluting balloons to market, covering the coronaries and lower-extremity vessels — the only company worldwide with this distinction. It is a pioneer in the development and commercialization of lesion-specific solutions, including therapies for below-the-knee and carotid artery disease. “Medtronic’s acquisition of Invatec will accelerate the growth of our CardioVascular business, adding important new products for the coronary and peripheral vascular markets,” said Scott Ward, senior vice president at Medtronic and president of the CardioVascular business. “Invatec brings to Medtronic an established international business with a European center of technology development and manufacturing, as well as a strong history of delivering products and high-value solutions to the interventional market,” said Andrea Venturelli, co-founder, chief executive and technical officer of Invatec. Invatec co-founder Stefan Widensohler, vice president of global sales and marketing, said, “Our integration into Medtronic creates a tremendous opportunity to leverage Medtronic’s global scale and scope across geographies and functions, from R&D to sales and marketing, to advance the interventional treatment of cardiovascular disease.” Cardiovascular interventions represent the largest sector of the world medical device market, generating $10 billion annually on a global basis. A significant growth opportunity within this sector is peripheral vascular disease, a large and underserved market currently estimated at US$2 billion annually and growing faster than 10 percent per year. Approximately 20 million people in the United States and Western Europe alone suffer from peripheral vascular disease, which causes pain, reduces mobility, inhibits wound healing and leads to approximately 250,000 amputations per year. Medtronic says that with Invatec will be better positioned to address these and other unmet clinical needs in the treatment of cardiovascular disease, the world’s leading cause of death. To top